NURO: AI 评分 48/100 — AI 分析 (4月 2026)

NeuroMetrix, Inc. specializes in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes. The company's key products include DPNCheck, Quell, and the ADVANCE system, serving various healthcare professionals across multiple countries.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

NeuroMetrix, Inc. focuses on developing and marketing medical devices for nerve assessment and pain management, including DPNCheck for neuropathy and Quell for chronic pain relief. Operating in the medical device sector, the company targets diverse healthcare providers across the United States, Europe, Japan, China, and Mexico, facing competition in a dynamic market.

NURO是做什么的？

NeuroMetrix, Inc., established in 1996 and headquartered in Woburn, Massachusetts, is a healthcare company dedicated to designing, building, and marketing advanced medical devices. These devices stimulate and analyze nerve response, serving both diagnostic and therapeutic purposes. The company's evolution has centered on addressing unmet needs in the assessment and treatment of neurological disorders and chronic pain. Its primary products include DPNCheck, a nerve conduction test used for evaluating peripheral neuropathies like diabetic peripheral neuropathy; Quell, a wearable device designed for symptomatic relief and management of chronic pain; and the ADVANCE system, a platform used for performing nerve conduction studies. NeuroMetrix markets its products to a wide array of healthcare providers, including managed care organizations, endocrinologists, podiatrists, and primary care physicians. Additionally, they serve occupational health specialists, orthopedic and hand surgeons, pain medicine physicians, neurologists, and physical medicine and rehabilitation physicians. The company's geographic reach extends across the United States, Europe, Japan, China, the Middle East, and Mexico, reflecting a global approach to addressing nerve-related medical conditions.

NURO的投资论点是什么？

NeuroMetrix, Inc. presents a focused investment opportunity within the medical device sector, driven by its innovative products like DPNCheck and Quell. The company's gross margin of 57.3% indicates potential profitability, but its negative P/E ratio of -2.86 and profit margin of -281.0% raise concerns about current financial performance. Growth catalysts include expanding market penetration for Quell in the chronic pain management sector and increasing adoption of DPNCheck for early neuropathy detection. Key risks involve competition from established medical device companies and the need for sustained innovation to maintain market relevance. The company's high beta of 1.83 suggests significant volatility, requiring careful consideration of market conditions.

NURO在哪个行业运营？

NeuroMetrix, Inc. operates within the competitive medical device industry, which is characterized by rapid technological advancements and stringent regulatory requirements. The market for nerve assessment and pain management devices is growing, driven by an aging population and increasing prevalence of conditions like diabetes and chronic pain. Key trends include the adoption of wearable technology and the shift towards non-invasive diagnostic and therapeutic solutions. NeuroMetrix competes with larger, more established players in the medical device space, requiring a focus on innovation and strategic partnerships to maintain market share.

Medical - Devices

Healthcare

NURO有哪些增长机遇？

Expanding the market reach of Quell for chronic pain management represents a significant growth opportunity. The chronic pain market is estimated to be substantial, with a growing demand for non-pharmacological pain relief solutions. By increasing awareness and distribution of Quell through targeted marketing and partnerships with pain clinics, NeuroMetrix can capture a larger share of this market. This expansion can be achieved within the next 2-3 years.
Increasing adoption of DPNCheck for early detection of diabetic peripheral neuropathy offers another growth avenue. Early diagnosis of DPN can lead to better patient outcomes and reduced healthcare costs. By promoting DPNCheck to primary care physicians and endocrinologists, NeuroMetrix can drive adoption and increase sales. This growth can be realized through educational initiatives and demonstrating the clinical and economic benefits of early DPN detection, with potential gains within the next 1-2 years.
Developing and launching new products that leverage the company's expertise in nerve stimulation and analysis can drive future growth. This includes exploring new applications for its technology in areas such as neurorehabilitation and neuromodulation. Investing in research and development to create innovative products can position NeuroMetrix as a leader in the field and attract new customers. New product launches are anticipated within the next 3-5 years.
Expanding into new geographic markets, particularly in Asia and Latin America, presents a significant growth opportunity. These regions have a large and growing population with increasing healthcare needs. By establishing partnerships with local distributors and adapting its products to meet local requirements, NeuroMetrix can tap into these markets and increase its global presence. Market entry into these regions is projected within the next 2-4 years.
Securing strategic partnerships with managed care organizations and integrated delivery networks can drive adoption of NeuroMetrix's products and increase sales. By demonstrating the value proposition of its products in terms of improved patient outcomes and reduced healthcare costs, NeuroMetrix can gain preferred status with these organizations and secure contracts for widespread use of its products. These partnerships can be established within the next 1-2 years.

Gross margin of 57.3% indicates potential for profitability in NeuroMetrix's medical device sales.
Market capitalization of $0.01 billion reflects the company's current valuation in the healthcare sector.
Negative P/E ratio of -2.86 suggests the company is not currently profitable.
Profit margin of -281.0% indicates significant losses relative to revenue.
Beta of 1.83 indicates higher volatility compared to the overall market.

NURO提供哪些产品和服务？

Designs and builds medical devices that stimulate nerve response.
Creates devices that analyze nerve response for diagnostic purposes.
Markets medical devices for therapeutic purposes.
Offers DPNCheck for evaluating peripheral neuropathies.
Provides Quell, a wearable device for chronic pain management.
Develops the ADVANCE system for nerve conduction studies.

NURO如何赚钱？

Sales of medical devices (DPNCheck, Quell, ADVANCE system) to healthcare providers.
Distribution through managed care organizations, endocrinologists, podiatrists, and primary care physicians.
Direct sales and marketing efforts targeting specific medical specialties.

Managed care organizations.
Endocrinologists and podiatrists.
Primary care physicians.
Pain medicine physicians and neurologists.
Occupational health, orthopedic, and hand surgeons.

Proprietary technology in nerve stimulation and analysis.
Established products with clinical validation (DPNCheck, Quell).
Relationships with key healthcare providers and organizations.
Expertise in designing and marketing medical devices for nerve-related conditions.

什么因素可能推动NURO股价上涨？

Ongoing: Continued expansion of Quell's market presence in the chronic pain management sector.
Ongoing: Increasing adoption of DPNCheck for early detection of diabetic peripheral neuropathy.
Upcoming: Potential regulatory approvals for new product applications.
Upcoming: Strategic partnerships with managed care organizations and integrated delivery networks.
Ongoing: Positive clinical trial results supporting the efficacy of NeuroMetrix's products.

NURO的主要风险是什么？

Potential: Competition from larger, more established medical device companies.
Potential: Technological advancements rendering existing products obsolete.
Potential: Changes in healthcare regulations and reimbursement policies.
Potential: Product liability claims related to medical devices.
Ongoing: Negative profit margin and P/E ratio indicating financial losses.

NURO的核心优势是什么？

Proprietary technology in nerve stimulation and analysis.
Established products with clinical validation (DPNCheck, Quell).
Distribution network reaching various healthcare providers.
Expertise in designing and marketing medical devices for nerve-related conditions.

NURO的劣势是什么？

Negative profit margin and P/E ratio indicating financial losses.
Small market capitalization compared to larger competitors.
High beta suggesting significant stock volatility.
Reliance on a limited number of key products.

NURO有哪些机遇？

Expanding the market reach of Quell for chronic pain management.
Increasing adoption of DPNCheck for early detection of diabetic peripheral neuropathy.
Developing and launching new products leveraging existing technology.
Expanding into new geographic markets in Asia and Latin America.

NURO面临哪些威胁？

Competition from larger, more established medical device companies.
Technological advancements rendering existing products obsolete.
Changes in healthcare regulations and reimbursement policies.
Potential product liability claims.

NURO的竞争对手是谁？

Apogee Therapeutics, Inc. — Focuses on biologics for inflammatory and immunological diseases. — (APGN)
China Jo-Jo Drugstores, Inc. — Operates retail drugstores in China. — (CJJD)
Centogene N.V. — Specializes in genetic diagnostics for rare diseases. — (CNTG)
Corvus Pharmaceuticals, Inc. — Develops cancer immunotherapies. — (CRVO)
ETAO International Co., Ltd. — Provides telemedicine and healthcare services in China. — (ETAO)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Shai N. Gozani
Headquarters: Woburn, US
Employees: 13
Founded: 2004

AI Insight

AI analysis pending for NURO

常见问题

What does NeuroMetrix, Inc. do?

NeuroMetrix, Inc. is a healthcare company that designs, builds, and markets medical devices focused on stimulating and analyzing nerve response. Its primary products include DPNCheck, a nerve conduction test for peripheral neuropathies; Quell, a wearable device for chronic pain management; and the ADVANCE system, a platform for nerve conduction studies. The company targets various healthcare professionals, including endocrinologists, podiatrists, and pain specialists, offering solutions for diagnosing and treating nerve-related conditions across the United States, Europe, Japan, China, the Middle East, and Mexico.

What do analysts say about NURO stock?

AI analysis is pending for NURO. However, based on available financial data, NeuroMetrix, Inc. has a market capitalization of $0.01 billion with a negative P/E ratio of -2.86 and a profit margin of -281.0%. The company's gross margin is 57.3%, and its beta is 1.83. These metrics suggest a volatile stock with current unprofitability. Analyst consensus and future growth prospects require further AI-driven analysis to provide a comprehensive evaluation.

What are the main risks for NURO?

NeuroMetrix, Inc. faces several risks, including intense competition from larger medical device companies with greater resources. Technological advancements could render the company's existing products obsolete, requiring continuous innovation. Changes in healthcare regulations and reimbursement policies could negatively impact sales and profitability. Product liability claims are a potential risk inherent in the medical device industry. Furthermore, the company's current negative profit margin and P/E ratio indicate financial instability and the need for improved financial performance.